Study Of Therapeutic Effect Of Desmopressin In The Treatment Of Nocturia In The Patients Who Referred To Urology Ward Of 501 I.R.I Army Hospital

Study Of Therapeutic Effect Of Desmopressin In The Treatment Of Nocturia In The Patients Who Refeered To Urology Ward Of 501 I.R.I Army Hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201010234989N1

Enrollment

Registered

2011-03-15

Start date

2009-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturia. Nocturia

Interventions

Intervention 1: Intervention Group: Desmopressin, 0.1mg, orally, at bed time for 8 weeks. Intervention 2: Control Group: Placebo, 0.1mg, orally, at bed time for 8 weeks.

Treatment - Drugs

Placebo

Intervention Group: Desmopressin, 0.1mg, orally, at bed time for 8 weeks

Control Group: Placebo, 0.1mg, orally, at bed time for 8 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion criteria: Nocturnal voiding at least 2 times or more Exclusin criteria: Drug noncompliance, uncontrolled diabetes mellitus, decompensated heart failure, Neurogenic bladder, Diabetes insipidus

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nocturnal Voiding Frequency. Timepoint: Before intervention, 4 weeks after intervention, 8 weeks after intervention. Method of measurement: Interview with patient.	—

Secondary

Measure	Time frame
Drug Adverse Effects. Timepoint: Before intervention, 4 weeks after intervention, 8 weeks after intervention. Method of measurement: Interview with patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Bijan Rezakhaniha

I.R.I Army University of Medical Sciences

reza.bijan@yahoo.com+98 21 2255 7435

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026